Arrowhead Pharmaceuticals (ARWR) Short Interest Ratio & Short Volume → Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (From Banyan Hill Publishing) (Ad) Free ARWR Stock Alerts $22.93 -0.20 (-0.86%) (As of 01:27 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Arrowhead Pharmaceuticals Short Interest DataCurrent Short Volume8,870,000 sharesPrevious Short Volume8,870,000 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$212.97 millionShort Interest Ratio / Days to Cover7.1Last Record DateApril 15, 2024Outstanding Shares123,900,000 sharesPercentage of Shares Shorted7.16%Today's Trading Volume257,260 sharesAverage Trading Volume1,430,058 sharesToday's Volume Vs. Average18% Short Selling Arrowhead Pharmaceuticals ? Sign up to receive the latest short interest report for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatARWR Short Interest Over TimeARWR Days to Cover Over TimeARWR Percentage of Float Shorted Over Time Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. Arrowhead Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20248,870,000 shares $212.97 million No ChangeN/A7.1 $24.01 3/31/20248,870,000 shares $253.68 million -3.6%N/A6.2 $28.60 3/15/20249,200,000 shares $260.18 million +4.1%N/A5.8 $28.28 2/29/20248,840,000 shares $283.76 million +0.8%N/A5.5 $32.10 2/15/20248,770,000 shares $259.33 million +13.6%N/A5.4 $29.57 1/31/20247,720,000 shares $247.81 million -13.0%N/A5 $32.10 Get the Latest News and Ratings for ARWR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20248,870,000 shares $323.13 million +18.7%8.8%5.8 $36.43 12/31/20237,470,000 shares $228.58 million -3.5%7.4%5 $30.60 12/15/20237,740,000 shares $220.98 million +1.6%7.7%6.3 $28.55 11/30/20237,620,000 shares $161.54 million -3.3%7.5%6.5 $21.20 11/15/20237,880,000 shares $212.84 million +9.9%7.8%7.9 $27.01 10/31/20237,170,000 shares $176.31 million +0.6%7.1%7.5 $24.59 10/15/20237,130,000 shares $189.66 million +19.0%7.0%7.5 $26.60 9/30/20235,990,000 shares $160.95 million -1.8%5.9%6.6 $26.87 9/15/20236,100,000 shares $176.41 million -3.6%6.0%6.7 $28.92 8/31/20236,330,000 shares $174.96 million +4.5%6.3%7.1 $27.64 8/15/20236,060,000 shares $177.86 million +8.8%6.0%6.8 $29.35 7/31/20235,570,000 shares $192.28 million +8.0%5.5%6.1 $34.52 7/15/20235,160,000 shares $178.54 million +9.3%5.0%5.2 $34.60 6/30/20234,720,000 shares $168.32 million -5.4%4.6%4.6 $35.66 6/15/20234,990,000 shares $178.34 million +1.0%4.9%5 $35.74 5/31/20234,940,000 shares $169.99 million -5.5%4.8%4.4 $34.41 5/15/20235,230,000 shares $208.62 million +8.1%5.1%4.5 $39.89 4/30/20234,840,000 shares $171.38 million -0.8%4.7%4.2 $35.41 4/15/20234,880,000 shares $148.64 million -1.6%4.7%4.7 $30.46 3/31/20234,960,000 shares $125.98 million -9.8%4.8%4.5 $25.40 3/15/20235,500,000 shares $139.26 million +19.1%5.3%4.9 $25.32 2/28/20234,620,000 shares $149.23 million -2.5%4.4%4.7 $32.30 2/15/20234,740,000 shares $161.40 million +3.5%4.6%4.9 $34.05 1/31/20234,580,000 shares $160.25 million -0.7%4.5%4.4 $34.99 1/15/20234,610,000 shares $169.74 million -2.7%4.5%4.6 $36.82 12/30/20224,740,000 shares $192.25 million +11.8%4.6%5 $40.56 12/15/20224,240,000 shares $133.31 million +7.1%4.2%4.8 $31.44 11/30/20223,960,000 shares $127.51 million +6.2%3.8%4.6 $32.20 11/15/20223,730,000 shares $125.55 million -4.4%3.6%4.5 $33.66 10/31/20223,900,000 shares $135.76 million -1.0%3.8%5 $34.81 10/15/20223,940,000 shares $126.16 million +1.8%3.9%5.1 $32.02 9/30/20223,870,000 shares $127.90 million -9.2%3.8%5.1 $33.05 9/15/20224,260,000 shares $149.65 million +1.9%4.2%5.4 $35.13 8/31/20224,180,000 shares $165.99 million -4.4%4.1%5.2 $39.71Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. ARWR Short Interest - Frequently Asked Questions What is Arrowhead Pharmaceuticals' current short interest? Short interest is the volume of Arrowhead Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 8,870,000 shares of ARWR short. Learn More on Arrowhead Pharmaceuticals' current short interest. What is a good short interest ratio for Arrowhead Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARWR shares currently have a short interest ratio of 7.0. Learn More on Arrowhead Pharmaceuticals's short interest ratio. Which institutional investors are shorting Arrowhead Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arrowhead Pharmaceuticals: Simplex Trading LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. How does Arrowhead Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Arrowhead Pharmaceuticals: IDEAYA Biosciences, Inc. (14.86%), Crinetics Pharmaceuticals, Inc. (6.63%), Xenon Pharmaceuticals Inc. (3.47%), Bausch Health Companies Inc. (5.81%), Amicus Therapeutics, Inc. (10.57%), MoonLake Immunotherapeutics (15.38%), ACADIA Pharmaceuticals Inc. (6.77%), HUTCHMED (China) Limited (0.30%), MorphoSys AG (1.02%), Evotec SE (0.02%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Arrowhead Pharmaceuticals stock? Short selling ARWR is an investing strategy that aims to generate trading profit from Arrowhead Pharmaceuticals as its price is falling. ARWR shares are trading down $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arrowhead Pharmaceuticals? A short squeeze for Arrowhead Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ARWR, which in turn drives the price of the stock up even further. How often is Arrowhead Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARWR, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: IDYA Short Squeeze CRNX Short Squeeze XENE Short Squeeze BHC Short Squeeze FOLD Short Squeeze MLTX Short Squeeze ACAD Short Squeeze HCM Short Squeeze MOR Short Squeeze EVO Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARWR) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsJeff Bezos Just Humiliated Elon MuskInvestorPlaceElon Musk Secret Crypto Plot ExposedCrypto 101 Media